Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics

Teladoc

Cathie Wood's Ark Invest ETFs added to their positions recently in two biotech stocks and one telehealth stock. All three stocks have plunged over the past couple of years.

Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?

Does Intellia Therapeutics, Inc. (NTLA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Intellia Therapeutics, Inc. (NTLA) is a Great Choice

The consensus price target hints at an 115.1% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Intellia Therapeutics, Inc. (NTLA) Could Surge 115.12%: Read This Before Placing a Bet

Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.

Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Securities Dae Gon Ha - Stifel Liisa Bayko - Evercore ISI William Pickering - Bernstein Joon Lee - Truist Brian Cheng - JPMorgan Rick Bienkowski - Cantor Fitzgerald Steve Seedhouse - Raymond James Silvan Tuerkcan - JMP Securities Richard Law - Credit Suisse Operator Good morning and welcome to the Intellia Therapeutics' First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.

Intellia Therapeutics, Inc. (NTLA) Q1 2023 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.41. This compares to loss of $1.96 per share a year ago.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today released its 2023 Corporate Responsibility report. The report provides a comprehensive update of the Company's performance and progress across key Environmental, Social and Governance (ESG) areas of focus.

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

Editas Medicine

Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it.

The 3 Most Promising Gene Editing Stocks to Buy in 2023

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

Axsome Therapeutics

CRISPR Therapeutics

Investors have shown keen interest in biotech after Johnson & Johnson's (NYSE: JNJ ) impressive earnings beat that topped Wall Street's expectations. The earnings beat reignited enthusiasm for biotech stocks, prompting investors to search for the next big players.

3 Biotech Stocks to Watch After Johnson & Johnson's Earnings Beat

Intellia Therapeutics: Signs Of Possible Life.

Intellia Therapeutics: Signs Of Possible Life

Vertex Pharmaceuticals

Precigen

Many investors look for growth opportunities wherever they can find them. If that describes you, then there are some high-growth biotech stocks that could present an opportunity.

3 High-Growth Biotech Stocks Poised for Success in 2023

CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase, MBA, to its board of directors. Mr. Chase will be a member of the audit committee and will succeed Caroline Dorsa as chair of the audit committee upon her retirement from the board. Ms. Dorsa is retiring from Intellia's board, effective June 15, 2023, as a result of her appointment as chair of Biogen's board of directors.

Intellia Therapeutics Names Bill Chase to its Board of Directors

Rivian Automotive

Intellia Therapeutics is a gene-editing company with lots of potential if it can get an approved treatment or therapy. Rivian Automotive plans to double its production in 2023 as its business generates strong growth.

2 Monster Growth Stocks That Can Double in Value, According to Wall Street

Against the backdrop of a solid day on Wall Street, CRISPR Therapeutics (NASDAQ: CRSP ) distinguished itself, popping up nearly 16%. The catalyst appears to center on CRISPR's single-dose therapy for sickle cell disease ( SCD ), which it's developing with Vertex Pharmaceuticals (NASDAQ: VRTX ).

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?

ARK Innovation ETF

Coinbase

Ginkgo Bioworks Holdings

Verve Therapeutics

Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.

Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global

Bausch + Lomb Corp

SparingVision appoints Jo seph C. Papa as Chairman

SparingVision appoints Joseph C. Papa as Chairman

Legend Biotech

Roivant Sciences Ltd

Ultragenyx Pharmaceutical

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

Exact Sciences

UiPath

Roku

Shopify

Block

Tesla

Twilio

Zoom Video

Cathie Wood (Catherine Duddy Wood) is the founder and CEO of ARK Invest. Before founding ARK Invest, Wood was with AllianceBernstein as Chief Investment Officer of Global Thematic Strategies.

These Are the Top 10 Holdings of Cathie Wood

Global X Genomics & Biotechnology ETF

CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of genetic material, as noted by the Cleveland Clinic.

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket

Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.

Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE.

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

Exelixis

2023 could be a landmark year for CRISPR Therapeutics. Exelixis has solid fundamentals, plus plenty of upside potential.

News for Intellia Therapeutics Stock (NTLA)